Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Double-Blind Randomized Placebo Controlled Age-Deescalating Trial of Two Virosome Formulated Anti-Malaria Vaccine Components (PEV 301 and PEV 302) Administered in Combination to Healthy Semi-Immune Tanzanian Volunteers.

Next Previous
X
Search
Trial Profile

A Phase Ib Double-Blind Randomized Placebo Controlled Age-Deescalating Trial of Two Virosome Formulated Anti-Malaria Vaccine Components (PEV 301 and PEV 302) Administered in Combination to Healthy Semi-Immune Tanzanian Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Malaria vaccine (Primary) ; Influenza virus vaccine
  • Indications Falciparum malaria; Malaria
  • Focus Adverse reactions; Pharmacodynamics

    • Most Recent Events

    • 18 Nov 2014 Results published in a Mymetics Corporation media release.
    • 01 May 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov record.
    • 09 Jan 2009 Actual start date (Dec 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top